Q4 2023 Earnings Summary
- Significant investments in 2024 are expected to drive accelerated growth and profitability in future years, especially in the Patient Direct segment where the company is adding over 70 commercial teammates whose positive returns begin after around 12 months, leading to higher long-term profits.
- A major new medical customer win will begin implementation in March 2024, expected to become one of Owens & Minor's top 10 customers, contributing meaningfully to revenue growth in 2024 and beyond.
- Demand for PPE is escalating, with customers burning through their existing inventory, leading to an uptick in demand in the Products & Healthcare Services segment, which should contribute to growth in 2024.
- The 2024 adjusted EBITDA guidance suggests the company may face challenges in meeting its ambitious 2028 targets, requiring a significant step-up in performance in the coming years. Analysts expressed concerns that the guidance of $550 million to $590 million for 2024 implies a need for a substantial increase to reach the $1 billion adjusted EBITDA target by 2028, potentially indicating execution risks. ( , )
- The company's increased investments in 2024 could pressure near-term profitability. Management acknowledged that 2024 is "more of an investment year," with significant spending on commercial personnel and technology that may not yield immediate returns, possibly impacting margins and earnings growth in the short term. ( , , , )
- Normalization of cash flow in 2024 may result in lower free cash flow compared to the exceptional 2023 levels, potentially slowing debt reduction efforts. The company anticipates operating cash flow to normalize after the record $741 million in 2023, with planned investments in inventory and working capital possibly reducing free cash flow and limiting the pace of net debt reduction. ( , )
-
2024 EBITDA Guidance and Future Outlook
Q: What are the assumptions in the 2024 EBITDA guidance?
A: Management stated that the 2024 EBITDA guidance of $550 million to $590 million factors in reinvesting the majority of the $100 million run-rate savings from their Operating Model Realignment into long-term growth initiatives. These include adding over 70 commercial teammates in Patient Direct, who typically break even after 12 months and then yield strong returns. They're also investing in expanding their proprietary product portfolio and network optimization, which will drive growth in the coming years. -
Free Cash Flow Normalization
Q: What is your expectation for free cash flow in 2024?
A: Management expects cash flow to normalize in 2024 following an extraordinary year in 2023. They anticipate ending the year with some debt paydown and leverage slightly above 3x. They plan to invest in inventory to support new wins, proprietary product expansion, and improved service levels. These are considered good reasons to invest in inventory and are expected to support long-term growth. -
Investment Year in 2024 and 2025 Expectations
Q: Is 2024 an investment year with growth accelerating in 2025?
A: Management indicated that 2024 is more of an investment year, with expected double-digit growth in adjusted EPS at the midpoint of their guidance. Investments in commercial personnel and technology in Patient Direct, as well as expanding the proprietary product portfolio in Products & Healthcare Services, will start yielding significant benefits in 2025 and beyond. -
CMS Reimbursement Changes Impact on Patient Direct Business
Q: Will potential CMS reimbursement changes affect Patient Direct revenue?
A: Management acknowledged that the OIG is reviewing CGM reimbursement, with findings expected in 2025. However, they do not anticipate any implications for their business at this time, noting that only 20% of Patient Direct revenue comes from government sources. -
PPE Inventory Levels Impact on 2024
Q: How will client PPE inventory levels affect you in 2024?
A: Management observed that while some customers still have excess PPE stock, demand is starting to slightly uptick. They expect PPE demand to ramp upward in 2024, particularly in categories like surgical products, as customers burn through existing inventory and surgery rates increase. -
New Medical Customer Win Contribution to 2024
Q: How will the new medical customer win contribute to 2024 guidance?
A: Management indicated that the new customer win will begin implementation in March and is considered meaningful, becoming one of their top 10 customers. It will start contributing to revenue in 2024, though specific financial details were not disclosed. -
Manufacturing Footprint and Red Sea Conflict Impact
Q: Has the Red Sea conflict affected your manufacturing plans?
A: Management stated that the conflict has not impacted their manufacturing footprint decisions. Their current manufacturing is primarily in North and Central America, with gloves produced in Thailand. Shipping channels are unaffected, as they use the Panama Canal or ship directly to the West Coast, experiencing minimal delays. Future manufacturing decisions will consider all potential risks and opportunities. -
West Virginia University Deal Delay
Q: Is the WVU Medicine deal delay impacting 2024 outlook?
A: Management explained that the delay is due to construction issues with the contractor and has no impact on 2024 results. They have extended their long-term deal with WVU and are currently serving the business from another distribution center until the new facility is completed. -
SG&A Uptick Due to Product Line Expansion
Q: Is the SG&A increase due to product line expansion?
A: Management confirmed that investments in personnel to expand the proprietary product portfolio are contributing to the SG&A uptick. These investments are part of long-term growth initiatives and are expected to yield benefits over time rather than serving as a near-term driver. -
LIFO Charge Impact on EBITDA
Q: How did LIFO charges affect your EBITDA results?
A: Management noted they had about $2 million of LIFO in 2023 and expect it to normalize in 2024 to be just over $50 million combined for LIFO and stock compensation adjustments. They acknowledged that fluctuations in LIFO and stock compensation contributed to difficulties in forecasting EBITDA in 2023.